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NMR spectroscopy was used to measure reduction potentials 
of four redox proteins by following multiple 15N HSQC 
protein resonances across a titration series using mixtures of 
oxidised and reduced glutathione. Results for PDI a, PDI ab 10 
and DsbA agree with the literature and our result for ERp18 
confirms this protein as an oxidoreductase of comparable or 
greater reducing strength than PDI a.  
In order for proteins to be stable and to conduct their catalytic 
functions efficiently, proteins must be correctly folded and the 15 
presence of disulphide bonds can ensure a protein folds correctly. 
A family of thiol-disulphide oxidoreductase proteins located 
within the cells catalyse the formation and rearrangement of 
disulphide bonds. Typically these enzymes contain an active site 
motif of CXXC and exist in either the oxidised or reduced state.1  20 
 PDI (protein disulphide isomerase) is located within the 
endoplasmic reticulum and aids in the folding of disulphide bond- 
containing proteins via the formation (oxidation), rearrangement 
(isomerisation) and removal (reduction) of non-native disulphide 
bonds. Human PDI is a 57 kDa protein that contains four 25 
thioredoxin-like domains in the order a, b, b’, a’ with an 
extended linker (x) between the b’ and a’ domains and an acidic 
19-residue C-terminal tail (c). The two catalytic a and a’ domains 
contain the conserved CGHC active site motif. The b and b’ 
domains, although non-catalytic, are considered essential for full 30 
PDI function, with the b domain providing structural stability and 
the b’ domain containing the primary ligand binding site.2-4 This 
study uses the a and ab domain fragments of human PDI (ca. 14 
and 27 kDa in size, respectively). To date, the PDI family 
contains up to 21 members with differing domain architectures1. 35 
ERp18, at 18 kDa, is one of the smallest known members of the 
PDI family with the thioredoxin fold and a CGAC active site.5, 6 
The fourth protein used in this study is E. coli DsbA, the 
archetypal disulphide oxidoreductase in bacteria.7 
 Determining redox potentials allows the identification of a 40 
protein’s role in vivo; proteins with low redox potentials in the 
region of -270 mV, such as thioredoxin,8 will have reducing 
properties, while proteins with higher reduction potentials around 
-122 mV, such as DsbA, will have oxidising properties.9 
Reduction potentials have typically been determined by 45 
monitoring reactions using tryptophan fluorescence10, or 
alternatively, using HPLC or radiolabelling. These methods 
operate by separating and quantifying the relative amounts of 
reduced and oxidised forms of the protein. However this method 
could only be applied to proteins with one active site. Recently, 50 
the reduction potentials of human PDI were elegantly determined 
using chemical modification and mass spectrometry to show the 
influence of adjacent active sites on re-oxidation of PDI by the 
protein Ero1α.11 This approach allows the measurement of two 
active sites simultaneously using a differential alkylation 55 
approach followed by mass spectrometry.  
 Measurement of the reduction potential using 15N HSQC has 
been achieved previously, which allowed monitoring of one 
active site cysteine in cytoplasmic desulfothioredoxin from 
Desulfovibrio vulgaris12 and 1D 1H NMR has been used to study 60 
reduction potentials in rubredoxin variants.13 Here we 
demonstrate a novel and much improved method with respect to 
using 15N HSQC NMR data. The cooperative mechanism 
whereby the protein switches between oxidised and reduced 
states enables a choice of two resonances to be monitored that 65 
mirror the conversion from one oxidation state to the other. In 
addition, all resonances that significantly shift between oxidised 
and reduced states are measured and each resonance provides a 
single Hill equation fit and reduction potential. Fitting each 
resonance to an individual curve fit provides the opportunity to 70 
identify and remove systematic and data specific errors to 
increase the precision and accuracy of the overall average 
reduction potential determined. Errors can be overlooked if all 
data is treated as one within an individual Hill plot.  
 Proof of concept is demonstrated for proteins containing one 75 
active site, however, it could easily be expanded to obtain redox 
potentials of proteins with two or more active sites. This would 
require NMR assignments to identify resonances from amino 
acids that report on each active site. Assignment of resonances to 
individual amino acids is summarised in the ESI†. Conversely, 80 
for proteins with a single active site, no residue-specific 
assignments are necessary, as only changes in each resonance are 
required to monitor the oxidative status.  
 15N enriched recombinant human PDI ab and ERp18 were 
expressed in E.coli and purified as previously described.2, 6 PDI a 85 
and DsbA were produced using protocols outlined in the ESI†.  
 To determine the reduction potential of PDI ab, PDI a, ERp18 
and DsbA different ratios of [GSH]/[GSSG] were used where the 
total concentration ([GSH]+[GSSG]) equalled 5 mM. All NMR 
data was obtained at 298 K using a 14.1 T (600 MHz 1H) Bruker 90 
Avance III NMR spectrometer equipped with a QCI-F cryoprobe. 
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All NMR samples were 330 µL within a Shigemi NMR tube and 
contained either 0.065mM (PDI a) or 0.3 mM (PDI ab, ERp18, 
DsbA) protein in 20 mM sodium phosphate buffer (pH 7.3) 
containing 50 mM sodium chloride and 5% (v/v) deuterium 
oxide. All buffers had nitrogen gas bubbled through them for 30-5 
60 min to ensure the removal of any dissolved oxygen and all 
proteins were found to reach redox equilibrium within 5 minutes 
of setting up each condition. All 15N HSQC spectra were acquired 
with 2048 points in the direct F2 dimension (1H) and 256 points 
in the F1 dimension (15N). NMR data processing was completed 10 
using NMRpipe and example spectra are shown in Figure 1. 
NMR backbone assignments have previously been completed for 
all the proteins2, 6, 14 and were used to identify the peaks that 
shifted with oxidation status. 
 15 
Fig. 1 15N HSQC spectra of (a) PDI a, (b) PDI ab, (c) ERp18 and (d) 
DsbA. Fully oxidised spectra are shown in red, and fully reduced spectra 
are shown in black. 
 Peak heights and volumes were determined using Analysis 
v2.215 for each oxidised and reduced peak in the spectrum. Peak 20 
volumes provided better curve fits for both the oxidised and 
reduced peaks. The fraction reduced was determined from this 
data and fitted in Kaleidagraph version 4.1 (Synergy Software) to 
the Hill equation to determine the equilibrium constant (Keq) 
using Equation 1, where Fred is the fraction of reduced protein. 25 
Example data fits to the Hill equation are shown in Figure 2, 
where millimolar concentrations were used to generate this plot. 
Therefore, Keq is solved from Equation 1 in millimolar units. 
Fred = ([GSH]2/[GSSG])/(Keq + [GSH]2/[GSSG])       (Eq.1) 
The reduction potential of each protein was then determined by 30 
the Nernst equation (Equation 2) where T = 298 K, n = 2, and the 
standard reduction potential of GSH (E’0(GSH)) = -240 mV.  If R is 
defined as the molar gas constant, Keq must be used with molar 
concentration units in Equation 2. 
Eʹ′0 = Eʹ′0(GSH) – (RT/nF) ln(Keq)                                  (Eq.2) 35 
Both equations have been described previously with respect to 
mass spectrometry reduction potential determination11 and are 
equally valid with our approach.  
 
Fig. 2 Two fits shown using  the Hill equation, PDI a, lysine 14 (green) 40 
with a redox potential of -144.43 ±0.34 mV  and DsbA serine 43 (red) 
with a redox potential of -124.63 ±0.98 mV. 
 Errors were determined using the Levenberg-Marquardt R-
value for the fit of the Hill equation and two controls were run; 
fully oxidised protein (in 5 mM GSSG) and fully reduced protein 45 
(in 5 mM dithiothreitol (DTT)). DTT was used as it is capable of 
fully reducing catalytic PDI domains. Individual plots are shown 
in the ESI†. Average reduction potentials and curve fit error 
values obtained by this method are summarised in Table 1. 
Table 1. Keq and mean reduction potential values (Eʹ′o) obtained including 50 
number of resonances used in final Keq and Eʹ′o analysis. 











Keq (mM) 0.59 1.59 2.61 0.16 
Eʹ′o (mV) -144.4 ±0.7 -156.8 ±1.2 -161.5 ±3.3 -125.6 ±0.6 
 
 This study has measured the reduction potential at one active 
site of the protein, however, the reduction potentials found in this 
study are similar to those previously determined.1, 8, 11 55 
 The use of multiple resonances to determine the reduction 
potential is extremely useful. For example, PDI a, which contains 
120 amino acids and one CGHC active site, provided 15N HSQC 
spectra with over 18 backbone amide cross peaks with significant 
chemical shift changes between the reduced and oxidised states. 60 
This provides a degree of data redundancy allowing weak or 
overlapped peaks to be removal from the analysis and a higher 
precision in the final value of the reduction potential determined. 
Across all moving resonances in PDI a, individual reduction 
potentials were calculated and ranged from -148.73 mV to -65 
140.39 mV. Using only optimal data from resonances that were 
not overlapped or of low signal to noise enables a value of -144.4 
±0.7 mV to be quoted. We also measured the reduction potential 
of PDI a and PDI ab as -144.6±1.1 mV and -157.0±2.1 mV 
respectively via single Hill plots that used all resonance data 70 
simultaneously; these plot are available in the ESI†. However, 
our approach provides smaller errors and hence greater precision 
because handling resonance data separately allows for the 
identification and exclusion of poor data. 
The values for PDI a are consistent with values previously 75 
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published, where the reduction potential varies from -110 mV16 to 
-190 mV.17  PDI ab data is also consistent and confirms that the 
addition of the structural b domain does not significantly alter the 
reduction potential of the catalytic a domain. This data confirms 
our method is equally applicable for larger proteins as PDI ab is 5 
ca. 27 kDa. The molecular weight limit for this method will be in 
excess of 60 kDa when acquiring TROSY optimised 15N-1H 
HSQC data. ERp18 provided a reduction potential of  -161.5 ±3.3 
mV that suggests this protein is slightly more reducing than PDI 
a. ERp18 was previous reported to have a similar reduction 10 
potential to PDI a, but the value reported was considered of low 
precision.5  The value obtained for DsbA is also within the range 
of that determined by other approaches.18, 19 
 When monitoring the redox changes in a protein, either peak 
height or volume could be used although peak volumes tended to 15 
provide better data fitting to the Hill equation and so was 
preferred. Our data reveals that reduction potentials for each 
protein could be determined by measuring peak volumes from 
only the reduced peak in the spectrum. Equally, the oxidised peak 
could be used to determine the fraction reduced, but care is 20 
required because NMR line broadening of the oxidised state 
resonance may complicate peak height or volume measurements. 
The effect of peak line broadening was demonstrated with Hill 
plots and associated reduction potentials obtained using only 
oxidised resonances for ERp18 and PDI a (data in ESI†). ERp18 25 
is known to exhibit relaxation line broadening in the oxidised 
state6 and the ESI† data demonstrates these data providing poor 
Hill plot fits and values even when spectrum sensitivity is not an 
issue as shown in Figure 1c and from oxidised and reduced 
ERp18 spectra displayed in the assignment section of the ESI†. 30 
We suggest that to prevent inaccuracy, all peak volumes or 
heights should be measured from either the oxidised or reduced 
state and not a mixture of the two forms. However, line 
broadening effects that alter quantitation could be managed by 
adjusting peak volumes or heights for relaxation using methods 35 
similar to those recently described in the study of metabolites.20  
 Overall, this method of measuring protein reduction potentials 
using 15N HSQC NMR is quick and convenient and has great 
potential to be utilised with proteins containing multiple active 
sites. This method can also probe the effect of physical and 40 
physiological conditions that influence the mechanistic process of 
disulphide bond biochemistry through different buffer systems, 
crowding agents and substrates. Whilst in this study the oxidation 
and reduction of the proteins were conducted using a 
[GSH]/[GSSG] mixture, this method could also be applied to 45 
alternative systems, for example [NADP]/[NADPH]. 
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